Cytokinetics Inc.

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company's drug candidates in clinical development are: omecamtiv mecarbil, a cardiac myosin activator for the potential treatment of heart failure, reldesemtiv, a skeletal muscle troponin activator for the potential treatment of amyotrophic lateral sclerosis and spinal muscular atrophy, CK-3773274, a cardiac myosin inhibitor, for the potential treatment of hypertrophic cardiomyopathy and AMG 594, a cardiac troponin activator.
  • TickerCYTK
  • ISINUS23282W6057
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for CYTK

ValuEngine Rating and Forecast Report for CYTK

ValuEngine Rating and Forecast Report for CYTK

ValuEngine Rating and Forecast Report for CYTK

A director sold after exercising options/sold 4,260 shares at 12.942USD and

A director at Cytokinetics Inc sold after exercising options/sold 4,260 shares at 12.942USD and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under ...

ValuEngine Rating and Forecast Report for CYTK

ValuEngine Rating and Forecast Report for CYTK

ValuEngine Rating and Forecast Report for CYTK

ValuEngine Rating and Forecast Report for CYTK

ValuEngine Rating and Forecast Report for CYTK

ValuEngine Rating and Forecast Report for CYTK

ValuEngine Rating and Forecast Report for CYTK

ValuEngine Rating and Forecast Report for CYTK

ValuEngine Rating and Forecast Report for CYTK

ValuEngine Rating and Forecast Report for CYTK

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • Homebuilders continue to be leadership. (ex. MTH, PHM, and MHO) • A number of Transportation Sector names are staging price and RS reversals, or remain leadership. (ex. XPO, JBLU, UAL, SKYW, AAL, DAL, UNP, JBHT, KNX, ODFL, LSTR, and SAIA) • Many Materials Sector names appear to be staging price and RS reversals. (ex. DOW, VVV, LYB, MLM, VMC, USCR, EMN, and CMC. )

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • A few Consumer Discretionary names continue to act well. (ex. UA, WHR, ELY, RRGB, SHAK, BOOT, ROST, WSM, and COTY) • The decline in oil prices may be helping some of the airlines. A few of them are near potential reversal points (ex. AAL and UAL) • Attractive Technology names include: (ex. UCTT, SEDG, FSLR, and TTEC)

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

• Offshore oil drillers continue to develop positively. Long-term trends are attractive. • Basic Materials are breaking down. The Sector is hitting a new RS lows. • The Financial Sector is also showing a sign of weakness as the RS is also hitting a new 52-week low. Not a good sign for the overall market.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch